Benefits of Metformin in Attenuating the Hallmarks of Aging

Ameya S. Kulkarni; Sriram Gubbi; Nir Barzilai

doi:10.1016/j.cmet.2020.04.001

Benefits of Metformin in Attenuating the Hallmarks of Aging

Ameya S. Kulkarni, Sriram Gubbi, Nir Barzilai

Medicine

Research output: Contribution to journal › Review article › peer-review

362 Scopus citations

Abstract

Metformin is the first drug to be tested for its age-targeting effects in a large clinical trial. In this perspective, Kulkarni et al. review how metformin acts on its primary and secondary targets to attenuate the hallmarks of aging, highlighting its utility as an effective gerotherapeutic intervention.

Original language	English (US)
Pages (from-to)	15-30
Number of pages	16
Journal	Cell metabolism
Volume	32
Issue number	1
DOIs	https://doi.org/10.1016/j.cmet.2020.04.001
State	Published - Jul 7 2020

Keywords

TAME
aging
aging hallmarks
health span
longevity
metabolism
metformin

ASJC Scopus subject areas

Physiology
Molecular Biology
Cell Biology

Access to Document

10.1016/j.cmet.2020.04.001

Cite this

@article{121006193a4141b39f1f051a52719f7b,

title = "Benefits of Metformin in Attenuating the Hallmarks of Aging",

abstract = "Metformin is the first drug to be tested for its age-targeting effects in a large clinical trial. In this perspective, Kulkarni et al. review how metformin acts on its primary and secondary targets to attenuate the hallmarks of aging, highlighting its utility as an effective gerotherapeutic intervention.",

keywords = "TAME, aging, aging hallmarks, health span, longevity, metabolism, metformin",

author = "Kulkarni, {Ameya S.} and Sriram Gubbi and Nir Barzilai",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = jul,

day = "7",

doi = "10.1016/j.cmet.2020.04.001",

language = "English (US)",

volume = "32",

pages = "15--30",

journal = "Cell metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Benefits of Metformin in Attenuating the Hallmarks of Aging

AU - Kulkarni, Ameya S.

AU - Gubbi, Sriram

AU - Barzilai, Nir

PY - 2020/7/7

Y1 - 2020/7/7

N2 - Metformin is the first drug to be tested for its age-targeting effects in a large clinical trial. In this perspective, Kulkarni et al. review how metformin acts on its primary and secondary targets to attenuate the hallmarks of aging, highlighting its utility as an effective gerotherapeutic intervention.

AB - Metformin is the first drug to be tested for its age-targeting effects in a large clinical trial. In this perspective, Kulkarni et al. review how metformin acts on its primary and secondary targets to attenuate the hallmarks of aging, highlighting its utility as an effective gerotherapeutic intervention.

KW - TAME

KW - aging

KW - aging hallmarks

KW - health span

KW - longevity

KW - metabolism

KW - metformin

UR - http://www.scopus.com/inward/record.url?scp=85086094819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086094819&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2020.04.001

DO - 10.1016/j.cmet.2020.04.001

M3 - Review article

C2 - 32333835

AN - SCOPUS:85086094819

SN - 1550-4131

VL - 32

SP - 15

EP - 30

JO - Cell metabolism

JF - Cell metabolism

IS - 1

ER -

Benefits of Metformin in Attenuating the Hallmarks of Aging

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this